Positive Long Term Results with Metvix® PDT in Basal Cell Carcinoma
PhotoCure announces crucial 12 months follow-up data on Basal Cell Carcinoma (skin cancer) patients unsuitable for standard therapy.PhotoCure is pleased to announce positive long- term recurrence data from its Metvix® photodynamic therapy (PDT) trial on patients with Basal Cell Carcinoma (BCC) lesions that were deemed unsuitable for standard therapy such as cryosurgery, surgery, reconstructive plastic surgery or irradiation. The data released today covering the 12 months follow-up period confirms the positive trends both in treatment response and clinical outcome announced earlier in the